Consumers across most of America will see their health insurance premiums go up next year for popular plans under President Barack Obama's health care law.
The U.S. economy grew at a solid 3.9 percent annual rate in the July-September period, even...
Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children with Spinal Muscular AtrophyNovember 25, 2014 10:58 am | News | Comments
Isis Pharmaceuticals, has announced the initiation of a pivotal Phase 3 study evaluating ISIS-...
Spark Therapeutics has announced today appointment of Daniel M. Takefman, Ph.D., as head of regulatory affairs. Dr. Takefman previously served as chief of the gene therapy branch of the Center for Biologics Evaluation and Research at the FDA, a position he held since 2006.
The scientist who developed the most widely accepted theory on aging that's used to study cancer and other diseases has died in Nebraska. Dr. Denham Harman developed the "Free Radical Theory of Aging" in 1954, though it took years for additional research to prove its importance.
An Italian doctor who contracted Ebola while working in Sierra Leone has arrived back in Italy and is being treated with the same experimental drugs used in the U.S. and other European countries to treat people infected with the virus.
Cocrystal Pharma, a biotechnology company developing novel antiviral therapeutics for human diseases, today announced the closing of its merger with RFS Pharma, a privately owned biotech company founded by renowned drug developer, Dr. Raymond Schinazi.
Mylan has confirmed that it and several subsidiaries have been sued by several Baxter subsidiaries in connection with the filing of an Abbreviated New Drug Application (ANDA) with the FDA for Esmolol HCl in Sodium Chloride Injection.
With new mAb drugs such as Kadcyla costing over 100,000 Euros per year, the price per patient for these therapies is considerably more than small molecule drug treatments. One reason for this is that these therapies cost more to manufacture than small molecules. By using mini scale bioreactor models to determine optimum scale-up bioprocess parameters in fed-batch culture could speed up process development and reduce manufacturing costs.
The PharmaSpray is an external lubrication system that sprays dry lubricant continuously onto tablet press punch tips and die walls. It delivers a consistent, validatable amount of dry lubricant onto the tablet’s outer surface over time.
Using too many teeth whiteners may damage your smile.
The Seven2Go portable meter is designed to provide fast quality data, single-handed operation, durability, and reliable pH measurement for laboratory, at-line, and outdoor environments.
Valeant Pharmaceuticals has received approval from the FDA for ONEXTON Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older.
WHO said a national task force has been set up to manage the outbreak, with the cost of the project reaching $200,000. The international health organization said it is working with the Red Cross and Madagascan health authorities to control the disease.
Whether they want to or not, consumers will soon know how many calories they are eating when ordering off the menu at chain restaurants, picking up prepared foods at supermarkets and even eating a tub of popcorn at the movie theater.
The head of the troubled Phoenix veterans' hospital was fired Monday as the Veterans Affairs Department continued its crackdown on wrongdoing in the wake of a nationwide scandal over long wait times for veterans seeking medical care and falsified records covering up the delays.
Two medicines Bayer HealthCare Pharmaceuticals Inc. is testing for respiratory disorders will get priority review by U.S. regulators and other benefits under a 2012 program to boost development of new antibiotics.
BMS and Five Prime Therapeutics to Evaluate Investigational Immunotherapies Opdivo and FPA008 in Six Tumor TypesNovember 24, 2014 4:09 pm | News | Comments
Bristol-Myers Squibb Company and Five Prime Therapeutics have entered into an exclusive clinical collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of combining Opdivo, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, with FPA008, Five Prime’s monoclonal antibody that inhibits colony stimulating factor-1 receptor.